Stephen SantoroPrincipal Scientist at Kite Pharma, a Gilead Company, USA
Stephen Santoro joined Kite/Gilead through the acquisition of Cell Design labs in 2017. While with Cell Design Labs, Stephen focused on the development of switchable CAR T technologies and associated next-generation tools. Currently, Stephen is leading Kite/Gilead’s internal multiple myeloma and acute myeloid leukemia research efforts.
Prior to joining Cell design labs, Stephen completed a postdoc at Genentech where he explored the role of the tumor stroma on checkpoint blockade and immunotherapy. Trained as a CAR T cell biologist at the University of Pennsylvania, Stephen believes that modulation of the tumor microenvironment using synthetic biology holds the key to successful CAR T cell therapy across multiple solid and semi-solid tumors